Investors Sell Shares of Pfizer (PFE) on Strength (PFE)

Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Friday. $41.48 million flowed into the stock on the tick-up and $80.32 million flowed out of the stock on the tick-down, for a money net flow of $38.84 million out of the stock. Of all companies tracked, Pfizer had the 3rd highest net out-flow for the day. Pfizer traded up $0.04 for the day and closed at $43.14

PFE has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, July 31st. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, July 31st. Bank of America upped their target price on shares of Pfizer from $42.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, August 1st. Morningstar set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, August 8th. Finally, Deutsche Bank set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, August 21st. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $42.67.

The company has a market capitalization of $256.57 billion, a price-to-earnings ratio of 16.28, a price-to-earnings-growth ratio of 2.15 and a beta of 0.88. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.03. The firm had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. Pfizer’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.67 EPS. As a group, research analysts expect that Pfizer Inc. will post 3 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.15%. The ex-dividend date of this dividend is Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.

In other Pfizer news, major shareholder Pfizer Inc purchased 55,556 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the purchase, the insider now directly owns 21,976,484 shares in the company, valued at $395,576,712. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of PFE. Capital World Investors boosted its stake in Pfizer by 124.8% during the 3rd quarter. Capital World Investors now owns 85,032,960 shares of the biopharmaceutical company’s stock worth $3,747,403,000 after purchasing an additional 47,202,436 shares during the period. AQR Capital Management LLC boosted its stake in Pfizer by 60.2% during the 3rd quarter. AQR Capital Management LLC now owns 23,151,759 shares of the biopharmaceutical company’s stock worth $1,020,298,000 after purchasing an additional 8,701,301 shares during the period. Charles Schwab Investment Advisory Inc. acquired a new stake in Pfizer during the 2nd quarter worth $286,229,000. Dimensional Fund Advisors LP boosted its stake in Pfizer by 15.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock worth $1,967,651,000 after purchasing an additional 7,059,171 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Pfizer by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 441,792,969 shares of the biopharmaceutical company’s stock worth $19,469,816,000 after purchasing an additional 6,620,749 shares during the period. Hedge funds and other institutional investors own 68.64% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Investors Sell Shares of Pfizer (PFE) on Strength (PFE)” was first reported by WKRB News and is the property of of WKRB News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.wkrb13.com/2018/11/24/investors-sell-shares-of-pfizer-pfe-on-strength-pfe.html.

Pfizer Company Profile (NYSE:PFE)

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Recommended Story: How to Invest in the Dividend Aristocrat Index

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply